BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,618,154 shares of the company’s stock after selling 12,788 shares during the period. Johnson & Johnson comprises 1.6% of BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s investment portfolio, making the stock its 3rd largest holding. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp owned approximately 0.06% of Johnson & Johnson worth $210,376,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also made changes to their positions in the company. Eagle Ridge Investment Management increased its stake in Johnson & Johnson by 3.5% during the 3rd quarter. Eagle Ridge Investment Management now owns 27,522 shares of the company’s stock worth $3,578,000 after buying an additional 928 shares during the period. Oliver Luxxe Assets LLC increased its stake in Johnson & Johnson by 12.7% during the 2nd quarter. Oliver Luxxe Assets LLC now owns 17,538 shares of the company’s stock worth $2,320,000 after buying an additional 1,972 shares during the period. Progressive Investment Management Corp increased its stake in Johnson & Johnson by 6.8% during the 3rd quarter. Progressive Investment Management Corp now owns 40,317 shares of the company’s stock worth $5,242,000 after buying an additional 2,584 shares during the period. Middleton & Co Inc MA increased its stake in Johnson & Johnson by 40.5% during the 3rd quarter. Middleton & Co Inc MA now owns 39,272 shares of the company’s stock worth $5,106,000 after buying an additional 11,315 shares during the period. Finally, Sitrin Capital Management LLC increased its stake in Johnson & Johnson by 1.6% during the 2nd quarter. Sitrin Capital Management LLC now owns 48,986 shares of the company’s stock worth $6,480,000 after buying an additional 792 shares during the period. 67.35% of the stock is currently owned by hedge funds and other institutional investors.
In other news, VP Paulus Stoffels sold 155,342 shares of the company’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total value of $20,172,712.12. Following the completion of the transaction, the vice president now owns 357,906 shares in the company, valued at approximately $46,477,673.16. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 0.19% of the company’s stock.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. The business had revenue of $20.20 billion during the quarter, compared to analysts’ expectations of $20.08 billion. During the same quarter in the prior year, the business posted $1.58 EPS. The company’s revenue for the quarter was up 11.5% on a year-over-year basis. sell-side analysts expect that Johnson & Johnson will post 8.11 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.53%. The ex-dividend date is Monday, February 26th. Johnson & Johnson’s payout ratio is 61.88%.
Several research analysts have commented on the stock. Wells Fargo & Co reiterated an “outperform” rating and set a $160.00 price target (up previously from $155.00) on shares of Johnson & Johnson in a report on Friday, January 12th. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 price target for the company in a report on Thursday, January 11th. Credit Suisse Group set a $154.00 price target on shares of Johnson & Johnson and gave the stock a “hold” rating in a report on Monday, January 22nd. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, January 9th. Finally, Stifel Nicolaus boosted their price target on shares of Johnson & Johnson from $142.00 to $145.00 and gave the stock a “hold” rating in a report on Wednesday, January 24th. Four analysts have rated the stock with a sell rating, nine have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Johnson & Johnson presently has an average rating of “Hold” and an average target price of $146.26.
COPYRIGHT VIOLATION WARNING: “Johnson & Johnson (JNJ) Position Trimmed by BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/03/13/johnson-johnson-jnj-position-trimmed-by-british-columbia-investment-management-corp.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.